Targeting EGFR and VEGF(R) pathway cross-talk in tumor survival and angiogenesis

• Published in: Pharmacology & therapeutics (Oxford) 2011-07, Vol.131 (1), p.80-90
• Main Authors: Larsen, Annette K, Ouaret, Djamila, El Ouadrani, Karima, Petitprez, Amélie
• Format: Article
• Language: English
• Subjects: Animals; Cell Survival - drug effects; Green Fluorescent Proteins - genetics; Green Fluorescent Proteins - metabolism; Humans; Molecular Targeted Therapy - methods; Neoplasms - blood supply; Neoplasms - drug therapy; Neoplasms - metabolism; Neoplasms - pathology; Neovascularization, Pathologic - drug therapy; Neovascularization, Pathologic - metabolism; Receptor Cross-Talk; Signal Transduction - drug effects; Vascular Endothelial Growth Factors - metabolism
• ISSN: 0163-7258; 1879-016X
• DOI: 10.1016/j.pharmthera.2011.03.012

The last decade has witnessed the approval of monoclonal antibodies (mAbs) and small molecule tyrosine kinase inhibitors (TKIs) for targeting of oncogenic signaling pathways. Generally, the clinical activity of these agents has been less than expected, in part due to unsuspected feed-back loops and cross-talk between different signaling pathways, thereby suggesting the interest of inhibiting multiple pathways. The extensive degree of EGFR-VEGF(R) pathway cross-talk identifies these pathways as particularly promising for joint targeting. Activation of the EGFR pathway increases the production of tumor-derived VEGF that acts on endothelial cells in a paracrine manner to promote angiogenesis. Accordingly, exposure to EGFR inhibitors is accompanied by attenuation of VEGF expression while resistance to EGFR inhibitors is frequently associated with enhanced VEGF levels. Recent data have expanded the biological activities of the two pathways by documenting a role for VEGF signaling in tumor cell survival and demonstrating the expression of EGFR by some tumor-associated endothelial cells. At least part of these signaling events are intracrine (intracellular and autocrine) and thus not readily accessible for the mAbs which target extracellular ligands and membrane receptors. This may explain why two major clinical trials combining EGFR and VEGF-targeted mAbs gave disappointing results and suggest a need for compounds that are able to inhibit intracrine signaling. Clinical application of new combinations should be preceded by preclinical development guided by functional biomarker analysis to identify active drug combinations and to facilitate the identification of patient subgroups likely, or not, to respond to dual pathway inhibition.